Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCZY Abcam		$0.00	$11.26 ▼ $19.73	$3.98B	1.29	4,712 shs	5,400 shs
GMAB Genmab A/S	$21.78 +0.5%	$21.66	$17.24 ▼ $28.43	$13.90B	0.95	989,805 shs	1.20 million shs
GNMSF Genmab A/S	$222.23	$214.29	$170.00 ▼ $292.80	$14.68B	0.91	31 shs	N/A
MRNA Moderna	$27.60 -6.6%	$29.22	$23.15 ▼ $91.99	$11.43B	1.83	8.23 million shs	16.27 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCZY Abcam	0.00%	0.00%	0.00%	0.00%	0.00%
GMAB Genmab A/S	+0.51%	-6.92%	+6.56%	+1.40%	-23.01%
GNMSF Genmab A/S	0.00%	-2.04%	+8.40%	+0.97%	-19.90%
MRNA Moderna	-6.63%	-19.18%	-8.85%	-0.04%	-76.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCZY Abcam	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	3.5405 of 5 stars	3.3	3.0	0.0	0.0	3.3	0.0	3.1
GNMSF Genmab A/S	0.552 of 5 stars	0.0	3.0	0.0	0.0	1.1	0.0	1.3
MRNA Moderna	4.4648 of 5 stars	4.0	1.0	0.0	4.6	3.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCZY Abcam	0.00	N/A	N/A	N/A
GMAB Genmab A/S	2.64	Moderate Buy	$37.80	73.55% Upside
GNMSF Genmab A/S	0.00	N/A	N/A	N/A
MRNA Moderna	2.04	Hold	$46.11	67.07% Upside

Current Analyst Ratings Breakdown

Latest ABCZY, GNMSF, GMAB, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/1/2025	MRNA Moderna	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$32.00
8/1/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$26.00
8/1/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
8/1/2025	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$32.00
7/22/2025	MRNA Moderna	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$26.00 ➝ $25.00
7/13/2025	MRNA Moderna	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
7/13/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
7/13/2025	MRNA Moderna	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold ➝ Hold
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/22/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$33.00 ➝ $26.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCZY Abcam	$336.37M	0.00	N/A	N/A	N/A	NaN
GMAB Genmab A/S	$3.12B	4.48	$1.52 per share	14.29	$8.04 per share	2.71
GNMSF Genmab A/S	$3.12B	4.70	$15.19 per share	14.63	$80.53 per share	2.76
MRNA Moderna	$3.24B	3.30	N/A	N/A	$28.33 per share	0.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCZY Abcam	N/A	N/A	0.00	0.00	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	$1.14B	$1.76	12.38	12.24	6.58	35.11%	18.08%	14.52%	8/7/2025 (Estimated)
GNMSF Genmab A/S	$1.14B	$17.63	12.61	∞	N/A	35.11%	19.23%	15.44%	8/7/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	N/A

Latest ABCZY, GNMSF, GMAB, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GMAB Genmab A/S	$0.39	N/A	N/A	N/A	$5.77 billion	N/A
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/8/2025	Q1 2025	GNMSF Genmab A/S	$1.88	$3.05	+$1.17	$3.05	$761.09 million	$765.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCZY Abcam	$0.07	0.36%	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
GNMSF Genmab A/S	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCZY Abcam	N/A	N/A	N/A
GMAB Genmab A/S	N/A	5.34	5.32
GNMSF Genmab A/S	N/A	5.34	5.32
MRNA Moderna	N/A	4.22	4.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCZY Abcam	N/A
GMAB Genmab A/S	7.07%
GNMSF Genmab A/S	N/A
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
ABCZY Abcam	N/A
GMAB Genmab A/S	1.54%
GNMSF Genmab A/S	1.54%
MRNA Moderna	11.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCZY Abcam	1,750	205.08 million	N/A	Not Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
GNMSF Genmab A/S	2,682	66.08 million	65.06 million	Not Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable

ABCZY, GNMSF, GMAB, and MRNA Headlines

Recent News About These Companies

Here's What Key Metrics Tell Us About Moderna (MRNA) Q2 Earnings

August 1 at 7:01 PM | zacks.com

MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View

August 1 at 2:26 PM | zacks.com

Moderna’s Bancel Nay on M&A, Yay on R&D Partnerships

August 1 at 1:19 PM | biospace.comB

Despite ongoing decline, Moderna's Spikevax sales beat expectations in Q2

August 1 at 1:19 PM | fiercepharma.comF

UK court finds Moderna patent infringed by BioNTech/Pfizer’s Comirnaty

August 1 at 1:19 PM | thepharmaletter.comT

Moderna's Key Patent Win Overshadowed By Gloomy Outlook

August 1 at 1:19 PM | aol.comA

Why Moderna (MRNA) Stock Is Trading Lower Today

August 1 at 1:19 PM | finance.yahoo.com

Moderna cuts sales forecast on UK revenue delay, shares fall

August 1 at 1:19 PM | reuters.com

Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript

August 1 at 12:04 PM | seekingalpha.com

Moderna slashes full-year sales outlook, reduces headcount

August 1 at 11:23 AM | proactiveinvestors.com

Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay

August 1 at 11:10 AM | investopedia.com

Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates

August 1 at 9:11 AM | zacks.com

Moderna: Q2 Earnings Snapshot

August 1 at 8:19 AM | sfgate.com

Moderna lowers top end of revenue guidance as vaccine group targets cost cuts

August 1 at 8:19 AM | finance.yahoo.com

Moderna Logs Sales Beat Despite Declining Vaccine Demand

August 1 at 8:19 AM | msn.com

Moderna Stock Dives After Earnings Report. What Has Wall Street Worried.

August 1 at 8:19 AM | msn.com

Moderna (NASDAQ:MRNA) Exceeds Q2 Expectations But Stock Drops

August 1 at 8:19 AM | finance.yahoo.com

Moderna drops after narrowing 2025 revenue outlook

August 1 at 8:19 AM | msn.com

Moderna Stock Drops After Earnings Report. What Has Wall Street Worried.

August 1 at 7:23 AM | barrons.com

Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts

August 1 at 7:08 AM | reuters.com

Private Advisor Group LLC Sells 13,174 Shares of Moderna, Inc. (NASDAQ:MRNA)

August 1 at 4:38 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCZY, GNMSF, GMAB, and MRNA Company Descriptions

Abcam OTCMKTS:ABCZY

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Genmab A/S NASDAQ:GMAB

$21.78 +0.11 (+0.51%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$21.78 0.00 (0.00%)

As of 08/1/2025 05:59 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S OTCMKTS:GNMSF

$222.23 0.00 (0.00%)

As of 07/31/2025

Moderna NASDAQ:MRNA

$27.60 -1.96 (-6.63%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$27.72 +0.13 (+0.45%)

As of 08/1/2025 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time